close

Enter

Log in using OpenID

PharmaPoint, Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

embed
Big Market Research present “PharmaPoint: Prostate Cancer - Global Drug Forecast and Market” Size, Share, Industry Trends, Demand, Analysis, Research, Report, Company Profiles, Forecast to 2023. Visit for more info @ http://www.bigmarketresearch.com
PharmaPoint: Prostate Cancer
Global Drug Forecast and Market Analysis to 2023
Report Description:
Summary
Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It
accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on
healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can
be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer
(CRPC) have no curative options.
Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreons
Provenge, Sanofis Jevtana, Johnson & Johnsons Zytiga, Medivation/Astellas Xtandi, and Bayers
Xofigo. During the forecast period from 2013-2023, GlobalData expects that nine new latestage pipeline agents will launch, eight of which will be for the treatment of CRPC. As a result
of this unprecedented level of clinical development, GlobalData predicts there will be massive
changes in the CRPC treatment paradigm. In addition, due to the influx of new therapies, the
size of the prostate cancer market across the nine major pharmaceutical markets (9MM) (US,
France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase three-fold.
Read more details at : http://www.bigmarketresearch.com/pharmapoint-prostate-cancerglobal-drug-forecast-and-analysis-to-2023-market
Report Description:
Key Questions Answered
- How will prostate cancer disease management change as new agents enter the market?
- Which prostate cancer patients have the greatest unmet needs and how well will these
needs be addressed by the new agents?
- What are the most dominant players in the prostate cancer space and what corporate
strategies are pursued by these companies?
- What are the most promising late-stage pipeline agents for prostate cancer.How do they
compare to currently marketed products?
- What opportunities will remain for future players following the launch of these pipeline
agents?
Table of Contents:
Key Findings
- The prostate cancer market, in the 9MM is forecasted to rapidly increase from $2.6bn in
2013 to $8.3bn in 2023, at a CAGR of 12.4%. This growth will be driven by the label
extensions of currently marketed drugs as well as the launch of nine new premium-priced
therapies for the treatment of prostate cancer.
- GlobalData expects Medivation and Astellas Xtandi will become the market leader in
prostate cancer. Xtandi is currently approved for pre- and post-chemotherapy metastatic
castration-resistant prostate cancer (CRPC). Over the course of the forecast period,
GlobalData anticipates it will receive label extensions in non-metastatic CRPC and hormonesensitive prostate cancer, making it available to virtually all prostate cancer patients
segments, with the exception of those with localized disease.
- The prostate cancer pipeline is robust with nine drugs in late-stage development. While
androgen biosynthesis is still a major target, many of the pipeline candidates have diverse
mechanisms of action and target proteins and pathways that are not targeted by the
currently marketed prostate cancer treatments. Among these new candidates are a
checkpoint inhibitor, a clusterin inhibitor, and an anti-angiogenic agent.
Table of Contents:
Scope
- Overview of prostate cancer, including epidemiology, etiology, pathophysiology, clinical
staging, symptoms, prognosis, quality of life, and disease management.
- Annualized prostate cancer therapeutics market revenue from 2013-2023. Annual cost of
therapy, and major marketed and pipeline drug sales in this forecast period are included.
- Key topics covered include strategic competitor assessment, market characterization,
unmet needs, and implications for the prostate cancer therapeutics market.
- Pipeline analysis: The prostate cancer pipeline is robust with many late-stage candidates set
to launch in the forecast period. Comprehensive analysis of the nine most promising
candidates in Phase III development are highlighted and profiled.
- Analysis of the current and future market competition in the global prostate cancer
therapeutics market, including insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide qualitative analysis of its
implications.
Table of Contents:
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies with the most robust
pipeline.
- Develop business strategies by understanding the trends shaping and driving the 9MM
prostate cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the 9MM prostate cancer therapeutics
market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analysing the performance of various competitors.
- About Report: http://www.bigmarketresearch.com/report-enquiry/308046
FOR MORE DETAILS
Visit us at :
http://www.bigmarketresearch.com/pharmapoint-prostate-cancerglobal-drug-forecast-and-analysis-to-2023-market
Stay With Us:
TELEPHONE: + 1-800-910-6452
EMAIL:
[email protected]
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
1/--pages
Report inappropriate content